The Information : Nvidia Juggles Mixed Messages on Chip Longevity

Nvidia Juggles Mixed Messages on Chip Longevity

Nvidia wants customers to buy as many of its next-generation AI chips as possible. It also wants its customers to know their old AI chips will remain valuable for a long time. Can it manage both?

Nvidia has been able to grow so quickly because it has convinced big customers to shift almost completely to its latest and greatest hardware nearly every year. At the Computex conference in Taiwan in 2024, for example, Nvidia even shortened its release cycles for new hardware from two years to one to get clients to upgrade more frequently. And on Monday, Nvidia, OpenAI and SB Energy signed a deal to help OpenAI fill 8 gigawatts of space exclusively with Nvidia’s next-generation chips—which CEO Jensen Huang said could amount to $150 billion to $200 billion in revenue for Nvidia from each new generation of its hardware.

Each generation is much more powerful than the last—but also much more expensive, helping Nvidia’s profits skyrocket and keeping its margins fat. Now Nvidia is telling the market that its graphics processing units are an investable asset class—and can thus hold financial value for much longer. These two positions feel somewhat at odds.

Taking both sides makes sense in an environment of compute scarcity, however. There seems to be demand for any type of usable GPU a customer can get their hands on, whether it’s the newest Vera Rubin or an Ampere chip from several generations back. A longer life cycle for GPUs could be Nvidia’s hedge against the moment when demand doesn’t outpace supply.

Right now, bigger players absolutely want Nvidia’s newest Vera Rubin server racks. Cloud executives told me most of the demand they’re seeing from customers right now is for those racks, which are set to ship later this fall at around $7 million each. But right now, the biggest buyers are just a handful of players: cloud giants, Nvidia-supported neoclouds (like CoreWeave, Nebius, Nscale and Firmus), Nvidia-supported AI labs (like OpenAI) and, maybe, Wall Street quant firms.

The next phase of AI adoption, and thus the next big driver of demand for computing power, will likely come from a wider range of businesses than a handful of cloud and AI companies. Those customers will also likely be more cost-conscious—and they may not need the most powerful, most expensive Nvidia server racks. Market dynamics could also change: My colleague Ann reported today that some analysts and data center developers are worried there could be a glut of server chips due to holdups in building and powering up data centers. Some investors are also getting more concerned that big tech’s AI data center spending spree could lead to the accumulation of too much debt before the companies deliver the profits to back it up. The cloud giants could pull back on spending as well.

One credit executive said that as time goes on, only a few companies may need to keep switching to Nvidia’s newest hardware every year. Switching entails a lot of cost and risk that a large or decades-old business might not want to take on.

Lee Kestler, CEO of data center developer EdgeCore Digital Infrastructure, compared where the GPU market is going to what happened in the cellphone business when most users decided they were fine holding on to their devices for years. “The older models still make calls and text. Value isn’t directly related to ‘latest and greatest’ when it comes to use cases to keep revenue flowing,” he said.

If Nvidia amplifies the message that older-generation GPUs can be useful and financially valuable for a long time, that could push fewer people to want its forthcoming Rubin Ultras and make asset-backed debt harder to raise. Older or secondhand chips are also cheaper, and that would allow more customers to afford buying or renting Nvidia hardware. Last week, for example, CEO Jensen Huang said that Nvidia’s Ampere chips, first launched in 2020 and no longer in production, could be “mission-capable” through 2029, thanks to new software that can improve their performance.

Still, for now, most big buyers of GPUs aren’t changing how they account for them on balance sheets as a result of the chips’ longer lives. Most companies are still depreciating GPUs linearly over five or six years, data center and credit executives said. (That means GPUs lose a fifth or sixth of their value on a customer’s balance sheet each year.) If you come across a 10-year depreciation schedule for Nvidia hardware, let me know.

The Information : Tesla Readies August Launch of Cybercab, Its Robotaxi Without

Tesla Readies August Launch of Cybercab, Its Robotaxi Without a Steering Wheel

The Takeaway
  • Tesla targets August public launch for Cybercab robotaxi in Austin.
  • Cybercab is a purpose-built vehicle without steering wheel or pedals.
  • Robotaxi service is central to Tesla’s future revenue and AI strategy.

Tesla has told staff it is gearing up for a public launch of the Cybercab, its first vehicle designed without a steering wheel or brake pedal, intended for its autonomous ride-hailing service, Robotaxi. The company aims to start with a public rollout in Austin, Texas.

It plans to launch the Cybercab to the public in the city as soon as this month, according to people with knowledge of the plans. Tesla in recent weeks has been preparing for a launch with steps including test driving, offering employee rides on private roads and conducting training with local first responders, the people said.

The long-promised rollout of the futuristic two-seat vehicle designed to operate without a driver would mark a major step in Tesla’s effort to turn the Cybercab into a commercial product. Musk has heavily promoted both the Cybercab and Tesla’s Robotaxi autonomous ride service as central to the company’s future and a potentially significant source of revenue and profits.

Tesla has been spotted testing Cybercabs on public roads all over the country, including in Austin, since June but hasn’t yet offered rides on public roads or to the general public, testing only internally. In July, the company said it had started allowing employees to take Cybercab rides on private roads around its Austin campus and has been collecting feedback from them. The company took similar steps before it launched its first Robotaxi hub in Austin last year.

Tesla told staff it plans to begin the rollout by offering Cybercab rides to Tesla employees on public roads and then to start incorporating the vehicles into its Robotaxi service in Austin a few days after that, the people said.

While the end of August is currently the internal target for the public launch of the Cybercab, the timeline could change as Tesla continues to make final preparations. Musk said during its earnings call in July that because the Cybercab had been built on a new platform, Tesla had to “accumulate driving data that is specific to the Cybercab before we can put a lot of them on the road.”

Tesla did not respond to a request for comment.

Cybercab is one of very few vehicles to operate on public roads without a steering wheel or brake pedal. It represents a big step from a technology and regulatory perspective, because the vehicle is designed to operate without allowing a human driver to take control or step in if the self-driving system runs into trouble. The company has said it has remote operators that monitor the vehicle and can take over in the event of an emergency.

Amazon-backed Zoox received approval in July from the National Highway Traffic Safety Administration to begin offering commercial rides with its steering wheelless and brakeless vehicles. Before that approval, Zoox offered free rides but didn’t charge customers. It is unclear if Tesla plans to offer rides in the Cybercab for free or if the company has received regulatory approval to use the vehicle as part of a commercial service.

Tesla completed emergency training with first responders in Austin last week, teaching them how to handle issues with the Cybercab vehicles, such as how to move the vehicle out of the way if needed, a spokesperson for the city of Austin confirmed.

Tesla currently uses Model Ys equipped with autonomous driving software for its Robotaxi service. It’s unclear if the company plans to fully replace all Model Ys in its Austin fleet with Cybercabs or if it will add the vehicles to its existing fleet. Tesla currently has 186 Model Y vehicles registered for its Austin service, according to a Texas Department of Motor Vehicles dashboard.

Ramping up the use of its purpose-built Cybercab could help Tesla avoid the added work of adapting an existing consumer vehicle for its Robotaxi operations. For the Austin Robotaxi launch, Tesla modified its Model Y vehicles to add self-cleaning cameras for clearing debris and a second telecommunications unit, people with knowledge of the project said.

Musk has said Tesla plans to produce the Cybercab at scale and repeatedly described the vehicle as central to the company’s autonomous driving ambitions. Tesla began production of the Cybercab in Texas last month, though the company has since said it no longer expects to reach volume production of the vehicle in 2026.

Scaling Up

While Musk has big ambitions for building a business around autonomous vehicles, the company is still in the process of turning the service into a business with significant revenue.

Tesla reported during its most recent earnings report in July that it had accumulated 380,000 driverless miles across its Robotaxi hubs. For comparison, Waymo, which has been operating as a public commercial service since 2020, says it has accumulated more than 220 million driverless autonomous miles with riders.

Tesla’s Robotaxi service can be costly to operate. The company employs hundreds of safety operators who are tasked with testing the software and improving it in new markets, as well as assisting with the ride-hailing service in the Bay Area.

But Tesla has reduced the human oversight involved in launching in newer markets including Miami. It is using fewer safety operators and launching Robotaxi rides without employees initially riding in the vehicles.

Tesla has been increasing its spending on AI and autonomous driving infrastructure as it continues to build out its AI business. Last month during its quarterly earnings call, it reported that its capital expenditures had more than doubled from the previous year to nearly $5.8 billion, in large part due to spending on AI projects. That spending comes as Musk has increasingly positioned AI and autonomy as central to Tesla’s future, arguing that investors should not view the company simply as an automaker.

>>> US After Hours Summary: FLXS +11.9% and DUOT +5.4% higher on earnings; KURA

After Hours Summary: FLXS +11.9% and DUOT +5.4% higher on earnings; KURA +5.4% on CEO insider purchase; FN -5.9% and XP -1.3% lower on earnings

After Hours Gainers:

Companies trading higher in after hours in reaction to earnings/guidance: FLXS +11.9%, DUOT +5.4%

Companies trading higher in after hours in reaction to news: AMLX +14.5% (to announce topline results from Phase 3 LUCIDITY clinical trial of Avexitide), KURA +5.4% (CEO insider purchase), BFLY +4% (Director insider purchase), GHI +2% (sells Vantage at Loveland), PICS +2% (launches ChatGPT integration), PSN +1.7% (awarded a $664.8 mln Army contract), RKLB +0.4% (added to U.S. Space Force's $981 mln NITE-STAR IDIQ program)

After Hours Losers:

Companies trading lower in after hours in reaction to earnings/guidance: FN -5.9%, XP -1.3% (also to cancel treasury shares)

Companies trading lower in after hours in reaction to news: ANDG -5.6% (stock offering by selling shareholders), INDP -3% (stock offering by selling shareholders), CACI -1.3% (selected on $981 mln U.S. Space Force NITE-STAR IDIQ), INFQ -0.7% (to delay 10-Q filing), XOM -0.3% (TRGP signs new long-term, integrated midstream agreements with subsidiaries of XOM), WEN -0.2% (U.S. President to resign; to create new position of COO), FLY -0.1% (onboarded to NASA spacecraft processing contract at Vandenber)

FT : Ebola outbreak becomes DR Congo’s deadliest World Health Organization warns

Ebola outbreak becomes DR Congo’s deadliest
World Health Organization warns country has entered ‘intense transmission’ phase of the virus

The Ebola epidemic in the Democratic Republic of Congo has become the deadliest in the country’s history, with the World Health Organization warning that it is in “a phase of intense transmission”.

The DR Congo National Institute of Public Health on Sunday confirmed the total fatalities from the outbreak, which started about six months ago, at 2,325. That is still far short of the epidemic from 2014 to 2016 in west Africa which killed 11,310 people.

The number of reported cases and deaths hit a record during the most recent reporting week, according to the WHO. “The broader geographic spread and continued high mortality demonstrate the rapidly changing scope of this public health emergency,” it said.

The confirmed number of Ebola infections reached 4,945 on Sunday, including 101 new cases in the previous 24 hours, according to DR Congo health authorities.

The true number of infections could be much higher. London health analytics company Airfinity estimates infections during this outbreak to be five times above the officially reported figures.

“The 2014-16 west Africa outbreak remains the only meaningful comparator for where this could go if the trajectory is not reversed within weeks,” Airfinity said on Monday.


The Ebola epidemic in the Democratic Republic of Congo has become the deadliest in the country’s history, with the World Health Organization warning that it is in “a phase of intense transmission”.

The DR Congo National Institute of Public Health on Sunday confirmed the total fatalities from the outbreak, which started about six months ago, at 2,325. That is still far short of the epidemic from 2014 to 2016 in west Africa which killed 11,310 people.

The number of reported cases and deaths hit a record during the most recent reporting week, according to the WHO. “The broader geographic spread and continued high mortality demonstrate the rapidly changing scope of this public health emergency,” it said.

The confirmed number of Ebola infections reached 4,945 on Sunday, including 101 new cases in the previous 24 hours, according to DR Congo health authorities.

The true number of infections could be much higher. London health analytics company Airfinity estimates infections during this outbreak to be five times above the officially reported figures.

“The 2014-16 west Africa outbreak remains the only meaningful comparator for where this could go if the trajectory is not reversed within weeks,” Airfinity said on Monday.


Speaking last week after a visit to DR Congo, WHO director-general Tedros Adhanom Ghebreyesus said: “The outbreak had a big head start, it is still way ahead of us, and we are playing catch-up.”

“There are chains of transmission we don’t know about, and until we know about — and break — every chain of transmission, we will not stop the outbreak,” said Tedros.

Manenji Mangundu, Oxfam’s country director in DR Congo, said that the collapse of sanitation and hygiene infrastructure was making it harder to contain the crisis, which had been deepened by conflict and aid cuts.

“Most deaths continue to occur within communities, which shows that too many cases still go undetected,” he said. “This is a disaster unfolding right before our eyes, and it is the result of political choices. We urgently need proper funding to be restored.”

The first two vaccines designed specifically to protect against Bundibugyo virus recently started phase 1 safety trials in human volunteers. Both are based on technology used first to develop Covid-19 vaccines.

One candidate was developed by Moderna, the US-based mRNA company. The other candidate comes from the University of Oxford. The Serum Institute of India (SII) has already manufactured 620,000 doses of the Oxford vaccine candidate for potential future use.

In addition, the WHO plans to start a trial of an existing vaccine made by the US company Merck to prevent the Zaire strain of Ebola to assess its effectiveness against Bundibugyo.

Although none of these vaccines can be deployed in the immediate future, an effective one would make a big difference, said Jean-Nicolas Armstrong Dangelser, a veteran of MSF campaigns against Ebola. In the 2018-2020 outbreak “being able to deploy vaccination campaigns and strategies changed the dynamic of our response,” he said.

>>> US Research Calls

Research Calls I
  • Upgrades:
    • Apple (AAPL) upgraded to Buy from Neutral at Rothschild & Co Redburn, tgt $400
    • Astera Labs (ALAB) upgraded to Outperform from Market Perform at Northland, tgt $350
    • CAE (CAE) upgraded to Outperform from Sector Perform at RBC Capital
    • Global Net Lease (GNL) upgraded to Outperform from Market Perform at BMO Capital, tgt $10
    • Mobileye (MBLY) upgraded to Buy from Hold at Berenberg, tgt $11
    • Okta (OKTA) upgraded to Overweight from Equal Weight at Wells Fargo, tgt $180
    • PennyMac Mortgage Investment Trust (PMT) upgraded to Buy from Hold at Deutsche Bank, tgt $12
    • YPF (YPF) upgraded to Buy from Hold at HSBC, tgt $60
  • Downgrades:
    • Amcor (AMCR) downgraded to Neutral from Overweight at JPMorgan, tgt $47
    • Bain Capital Specialty Finance (BCSF) downgraded to Market Perform at Keefe, Bruyette & Woods, tgt $13
    • Crescent BDC (CCAP) downgraded to Market Perform at Keefe, Bruyette & Woods, tgt $12
    • Kinetik Holdings (KNTK) downgraded to Hold from Buy at Clear Street, tgt $57
    • Netskope (NTSK) downgraded to Hold from Buy at Deutsche Bank
    • PLDT (PHI) downgraded to Neutral from Overweight at JPMorgan
    • SentinelOne (S) downgraded to Hold from Buy at Deutsche Bank
    • Shopify (SHOP) downgraded to Accumulate from Buy at Phillip Securities, tgt $170
    • Workday (WDAY) downgraded to Neutral from Buy at BTIG
    • Workday (WDAY) downgraded to Hold from Buy at Deutsche Bank, tgt $220
    • York Space Systems (YSS) downgraded to Neutral from Overweight at JPMorgan, tgt $17
  • Others:
    • ADT Inc. (ADT) initiated with a Neutral at BTIG
    • Alpha Compute (ALP) assumed with a Neutral at H.C. Wainwright
    • Columbia Financial (CLBK) initiated with an Outperform at Keefe, Bruyette & Woods, tgt $14.50
    • Dave (DAVE) initiated with an Overweight at Piper Sandler, tgt $390
    • Deep Isolation Nuclear (DBHL) initiated with a Buy at ThinkEquity, tgt $8
    • Etsy (ETSY) reinstated with a Neutral at Goldman Sachs, tgt $89
    • Federal Signal (FSS) initiated with a Buy at Citi, tgt $150
    • Freenome (FRNM) initiated with a Buy at BTIG, tgt $17
    • Freenome (FRNM) initiated with a Buy at Jefferies, tgt $17
    • Huntington Bancshares (HBAN) initiated with an Overweight at Wells Fargo, tgt $23
    • Immunic (IMUX) initiated with an Outperform at Wedbush, tgt $45
    • Odysight.ai (ODYS) initiated with a Buy at Chardan, tgt $7.15
    • Onto Innovation (ONTO) initiated with a Buy at Goldman Sachs, tgt $400
    • Pacira Pharmaceuticals (PCRX) reinstated with a Buy at Truist, tgt $30
    • Pulse Biosciences (PLSE) initiated with a Buy at Needham, tgt $58
    • SoFi Technologies (SOFI) initiated with an Overweight at Piper Sandler, tgt $22
    • Sunbelt Rentals (SUNB) initiated with an Overweight at Wells Fargo, tgt $96
    • Target Hospitality (TH) initiated with an Overweight at Morgan Stanley, tgt $22
    • Universal Music Group (UMGNF) reinstated with a Buy at Citi

>>> US Gapping down

Gapping down
In reaction to earnings/guidance
:
  • MOVE -1.9%, CUE -0.9%
Other news:
  • ENVX -7.7% (names CFO Ryan Benton interim CEO after Raj Talluri resigns; T.J. Rodgers becomes executive chairman)
  • XZO -1.8% (lower despite authorizing $25 mln stock repurchase program)
  • REPL -1.5% (files mixed securities shelf offering)
  • MAIR -1.4% (to acquire ebm-papst for $5.4 bln)
  • DT -1.3% (unit launches $1.25 bln private offering of exchangeable senior notes due 2031)
  • VOYG -1.1% (files mixed securities shelf offering)
  • GNK -1% (Diana Shipping withdraws bid for Genco after board demanded higher terms)
  • FJET -0.7% (to delay 10-Q filing)

>>> US Gapping up

Gapping up
In reaction to earnings/guidance
:
  • HTHT +9.4%, HIVE +8.8%, AMPG +1.9% (guidance), PPTA +1.8%
Other news:
  • OABI +20.1% (signs ion channel collaboration and license deal with Eli Lilly; raised its 2026 cash and cash equivalents financial guidance following recent technology licensing activity)
  • ARGX +10.5% (reports topline results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis)
  • PURR +9.3% (Duquesne (Stanley Druckenmiller) discloses new postion)
  • MESO +8.7% (completes patient treatment in pivotal Phase III chronic low back pain trial)
  • DSX +7.7% (Diana Shipping withdraws bid for Genco after board demanded higher terms) IPCX +6.3% (closes A1R water merger; combined company to trade as WATR on Aug. 17)
  • HCM +6.3% (says ORPATHYS plus AstraZeneca's TAGRISSO met PFS and OS goals in Phase III lung cancer trial)
  • FULC +4.8% (to merge with Slate Medicines in all-stock deal; backs transaction with $245 mln private placement)
  • SLN +4.2% (closes upsized ADS offering with full underwriters' option exercise)
  • NPK +4% (AMTEC Corporation announces option awards under AMTEC's current five-year 40mm systems contract)
  • EYPT +3.5% (says Phase III LUGANO missed primary endpoint in full dataset; DURAVYU showed non-inferiority in ad hoc analysis)
  • CRWV +2.5% (Appaloosa (David Tepper) discloses new position)
  • TTMI +2.5% (to acquire Epiq Solutions for about $1.1 bln in cash)
  • FTAI +2.2% (closes $2.0 bln warehouse financing facility for second Strategic Capital vehicle) IMC +2% (files for 10.11 mln ordinary share offering by selling shareholder)
  • INTC +1.6% (CEO Lip-Bu Tan bought 105,263 shares at $95 worth ~$10 mln)
  • GT +1.3% (Appaloosa (David Tepper) discloses new position)
  • PAYP +1.3% (ValueAct discloses new stake)

>>> US Early premarket gappers

Early premarket gappers
  • Gapping up:
    • OABI +18.9%, ARGX +10.4%, PURR +9.4%, MESO +9.1%, DSX +8%, HTHT +7.4%, IPCX +6.3%, SLN +6.1%, HIVE +5.4%, HCM +5.2%, FJET +4%, FTAI +3.6%, CRWV +3.1%, GNK +3.1%, TTMI +2.8%, INTC +2.4%, MOVE +2.4%, PPTA +1.9%, SPCX +1.5%, PAYP +1.3%, GSAT +1.3%, GT +1%, ACHV +0.8%, BMI +0.8%
  • Gapping down:
    • XZO -1.8%, VUZI -1.6%, CUE -0.9%, REPL -0.5%, MSGS -0.5%